Evidence map›Paper›PMID 36062198›Full record

ArticleJournal of King Saud University. Science2022

ZnO-chlorogenic acid nanostructured complex inhibits Covid-19 pathogenesis and increases hydroxychloroquine efficacy.

Mosleh M Abomughaid, Mohammed S Nofal, Khaled I Ghaleb, Mohamed G Seadawy, Miral G AbdEl-Wahab, Alaa S Hegazy, Doaa A Ghareeb

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of King Saud University. Science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Mosleh M AbomughaidMedical Laboratory Sciences Department, College of Applied Medical Sciences, University of Bisha, Bisha, Saudi Arabia.
Mohammed S NofalCenter of Excellency for Drug Preclinical Studies (CE-DPS), Pharmaceutical and Fermentation Industries Development Centre, City of Scientific Research and Technological Applications (SRTA-City), New Borg El-Arab, Alexandria, Egypt.
Khaled I GhalebMedical Laboratory Sciences Department, College of Applied Medical Sciences, University of Bisha, Bisha, Saudi Arabia.
Mohamed G SeadawyBiological Prevention Department, Egyptian Army, Egypt.
Miral G AbdEl-WahabCenter of Excellency for Drug Preclinical Studies (CE-DPS), Pharmaceutical and Fermentation Industries Development Centre, City of Scientific Research and Technological Applications (SRTA-City), New Borg El-Arab, Alexandria, Egypt.
Alaa S HegazyMedical Laboratories Department, Faculty of Allied Medical Science, Pharos University, Alexandria, Egypt.
Doaa A GhareebBio-screening and Preclinical Trial Lab, Biochemistry Department, Faculty of Science, Alexandria University, Alexandria, Egypt.
Alexandria University · EGCity of Scientific Research and Technological Applications · EGUniversity of Bisha · SAEgyptian Government · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The study purpose was to compare the anti- novel coronavirus disease 2019 (COVID-19) property of chlorogenic acid (CGA) and Zinc oxide nanoparticles (ZnO-NP) with the new valid synthesized complex of ZnO /CGA-NPs. Methods: The facile mixing method was utilized to prepare ZnO/CGA-NPs. The Results: The results confirmed that the uniformly dispersed ZnO-NPs were converted to aggregated form of ZnO/CGA-NPs upon the addition of CGA. The inhibitory concentration 50 (IC Conclusion: ZnO/CGA-NPs Complex can be considered as a new anti- severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) compound.

Indexed as

ACE2, angiotensin-converting enzyme 2CGA, chlorogenic acidsCOVID 19, coronavirus disease 2019HCQ, hydroxychloroquinePapain-like proteinasePlaque assayPLpro, papain-like proteinaseRBD, spike protein-receptor binding domainRNA dependent RNA polymeraseSARS-CoV-2, severe acute respiratory syndrome coronavirus 2VeroE6 toxicityZnO, Zinc oxide

Identifiers

PMID36062198
PMCPMC9425706
OpenAlexW4293581805

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.